Abstract| Volume 51, SUPPLEMENT 1, S11, March 2015

Download started.


ITOC2 – 032. Optimising active-specific immunotherapy in lymphodepleted mice with subcutaneous melanoma

      This paper is only available as a PDF. To read, Please Download here.


      Lymphodepletion, reconstitution and active-specific tumour cell vaccination (LRAST) enhances the tumour-specific immune response in a murine melanoma model. Myeloid derived suppressor cells (MDSC, Gr-1+ CD11b+) may decrease the induction of T-cells and their therapeutic efficacy. Aim of the study was to evaluate the benefit of MDSC depletion in addition to LRAST, using anti-Gr-1 antibody (Ab). The Gr-1 epitope is also expressed on CD8+ T-cells.


      Female C57BL/6 mice with subcutaneous (s.c.) D5 melanoma were lymphodepleted with cyclophosphamide and reconstituted with naïve splenocytes. Vaccination was performed with irradiated syngeneic mGM-CSF-producing D5G6 melanoma cells. For MDSC depletion, anti-Gr-1 Ab (clone RB6-8C5, 230 μg) was injected every other day starting on the day of lymphodepletion. Induction of tumour-specific T-cells in tumour vaccine draining lymph nodes was evaluated using interferon (IFN)-γ assays. Immune cells were analysed by flow cytometry. D5 tumour growth was monitored.


      Anti-Gr-1 administration had no long-lasting effect on MDSC elimination. The antibody also bound to CD8+ Gr-1+ CD44+ T memory cells. The combination of anti-Gr-1 treatment and LRAST enhanced tumour-specific IFN-γ release. Nevertheless, this did not translate into improved survival.


      Given an insufficient elimination of MDSC and the possible depletion of Gr-1+ memory T-cells, the use of anti-Gr-1 Ab in our tumour model seems questionable.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect